Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Finasteride
Drug ID BADD_D00898
Description Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures.[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss.[L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by _in situ_ high levels of DHT.[A178159] In the treatment of benign prostate hyperplasia, alpha-blockers such as [tamsulosin] and [terazosin] are also used. Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in benign prostate hyperplasia and androgenic alopecia, thus reducing the risk for secondary complications while providing symptom control.[A2132]
Indications and Usage For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostate. Also used for the stimulation of regrowth of hair in men with mild to moderate androgenetic alopecia (male pattern alopecia, hereditary alopecia, common male baldness).
Marketing Status Prescription; Discontinued
ATC Code D11AX10; G04CB01
DrugBank ID DB01216
KEGG ID D00321
MeSH ID D018120
PubChem ID 57363
TTD Drug ID D08IWD
NDC Product Code 68071-3380; 71335-0281; 71335-1898; 76420-074; 71335-0235; 63187-265; 14501-0013; 68645-541; 68788-6976; 65862-370; 68554-0022; 60687-428; 50090-1936; 53104-7714; 68071-4541; 68382-074; 0395-8239; 38779-2410; 71335-1530; 65862-927; 49452-3147; 62756-913; 64918-0706; 70771-1152; 71052-602; 63187-863; 43598-303; 68071-4167; 63629-8180; 65862-149; 76420-151; 71713-096; 71610-515; 68788-6875; 71335-0433; 57237-061; 76420-154; 50090-4697; 55154-8083; 71713-099; 50090-4648; 48087-0092; 55111-172; 71610-520; 64918-0422; 46144-345; 71335-1304; 16729-090; 50268-314; 70518-2287; 70518-2363; 76282-412; 51927-4847; 17856-0090; 67877-288; 51552-1470; 68071-3094; 43598-390; 55111-026; 51508-001; 68071-3306; 68071-3354; 78206-153; 50090-3942; 68071-4808; 16729-089; 53104-7549; 70518-0397; 69097-112; 31722-526; 70518-3182; 68981-021; 61919-733; 57237-062; 71335-1634; 55111-171; 35573-400; 0093-7355; 0904-6830; 67877-455; 68071-2620; 78206-152; 31722-525; 50090-1718
Synonyms Finasteride | Chibro-Proscar | Chibro Proscar | Propecia | Propeshia | MK-906 | MK 906 | MK906 | Proscar | Eucoprost
Chemical Information
Molecular Formula C23H36N2O2
CAS Registry Number 98319-26-7
SMILES CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Concussion17.11.01.004; 12.01.10.0050.000428%Not Available
Confusional state19.13.01.001; 17.02.03.0050.003100%
Conjunctivitis11.01.06.012; 06.04.01.0020.000321%
Constipation07.02.02.0010.003635%
Coordination abnormal17.02.02.0040.000428%Not Available
Coronary artery disease24.04.04.006; 02.02.01.0010.001283%Not Available
Costochondritis15.07.03.0010.000321%Not Available
Cough22.02.03.0010.002352%
Crohn's disease10.02.01.005; 07.08.01.0150.000321%Not Available
Crying17.02.05.013; 12.02.11.001; 08.01.03.005; 19.04.02.0020.000534%Not Available
Cryptorchism21.15.01.001; 05.05.02.002; 03.03.01.0010.000214%Not Available
Cyst16.02.02.002; 08.03.05.0010.001283%Not Available
Cystitis20.03.02.002; 11.01.14.0010.000321%
Dandruff23.03.16.0010.000534%Not Available
Deafness04.02.01.0010.000855%Not Available
Deafness neurosensory17.04.07.001; 04.02.01.0020.000534%Not Available
Death08.04.01.001--
Decreased immune responsiveness10.02.01.0410.000214%Not Available
Decreased interest19.15.02.0040.001283%Not Available
Dehydration14.05.05.001--
Dependence19.07.02.0030.000214%Not Available
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.0010.002352%Not Available
Depression19.15.01.0010.081671%
Depression suicidal19.15.01.0040.001069%Not Available
Dermal cyst23.10.02.001; 16.26.02.0010.001283%Not Available
Dermatitis23.03.04.0020.000962%Not Available
Dermatitis atopic23.03.04.016; 10.01.04.0040.000214%Not Available
Dermatitis contact12.03.01.040; 10.01.01.003; 23.03.04.0040.000534%Not Available
Dermoid cyst16.02.02.006; 03.05.01.0050.000321%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 35 Pages